{"slug":"mrna-cancer-vaccines","topic":"mrna-cancer-vaccines","title":"mRNA Therapeutics & Cancer Vaccines: State of the Field (October 2026)","summary":"Covers personalized neoantigen mRNA cancer vaccines, lipid-based delivery, self-amplifying and circular RNA, and mRNA immunotherapies beyond vaccination, with trial phases, registered endpoints and registry status as of October 2026. The key takeaway is that a randomized Phase 3 test of an individualized neoantigen mRNA vaccine, in high-risk melanoma (INTerpath-001), is registered as active, not recruiting, with no results posted; the sources in this dossier contain no outcome data for it, so its efficacy is not reported here. Most other evidence in the field is single-arm, early-phase or preclinical.","version":1,"published_at":"2026-10-30","updated_at":"2026-10-30","stats":{"words":3805,"citations":40,"claims":29,"timeline":13,"benchmarks":10,"open_problems":6,"key_papers":13,"glossary":14},"verification":{"status":"verified","method":"automated figure and citation-relevance triage against cited abstracts, plus targeted AI review with web checks of flagged statements; automated citation resolution","claims_checked":37,"issues_fixed":30,"verified_at":"2026-10-30"},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/mrna-cancer-vaccines","preview_url":"https://space-kitty.com/api/v1/dossiers/mrna-cancer-vaccines/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/mrna-cancer-vaccines","toc":[{"level":2,"text":"Executive summary","anchor":"executive-summary"},{"level":2,"text":"Background and core concepts","anchor":"background-and-core-concepts"},{"level":2,"text":"Timeline of key milestones","anchor":"timeline-of-key-milestones"},{"level":2,"text":"State of the art","anchor":"state-of-the-art"},{"level":3,"text":"Individualized neoantigen mRNA vaccines","anchor":"individualized-neoantigen-mrna-vaccines"},{"level":3,"text":"Shared, dendritic-cell and investigator-initiated programs","anchor":"shared-dendritic-cell-and-investigator-initiated-programs"},{"level":3,"text":"Computational antigen selection","anchor":"computational-antigen-selection"},{"level":3,"text":"Delivery: lipid nanoparticles, lipoplexes and polymers","anchor":"delivery-lipid-nanoparticles-lipoplexes-and-polymers"},{"level":3,"text":"Self-amplifying and circular RNA","anchor":"self-amplifying-and-circular-rna"},{"level":3,"text":"Non-vaccine mRNA immunotherapy","anchor":"non-vaccine-mrna-immunotherapy"},{"level":3,"text":"Quantitative benchmarks","anchor":"quantitative-benchmarks"},{"level":2,"text":"Open problems and active debates","anchor":"open-problems-and-active-debates"},{"level":2,"text":"Major programs and players","anchor":"major-programs-and-players"},{"level":2,"text":"Outlook: what to watch","anchor":"outlook-what-to-watch"},{"level":2,"text":"Key papers","anchor":"key-papers"},{"level":2,"text":"Glossary","anchor":"glossary"}],"sample_claims":["INTerpath-001 (NCT05933577) is a randomized, double-blind Phase 3 trial of intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab in high-risk cutaneous melanoma; the registry lists an estimated enrollment of 1,089.","The registry lists INTerpath-001 as active, not recruiting, with no results posted as of 2026-10-30; the sources in this dossier contain no outcome data for the trial, so no efficacy figures are reported for it."],"includes":["markdown","claims","timeline","benchmarks","open_problems","key_papers","glossary","bibliography"],"citation_count":40,"how_to_buy":"GET https://space-kitty.com/api/v1/dossiers/mrna-cancer-vaccines with an x402 client ($0.20, USDC on Base Sepolia (testnet))."}